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 Peptide fraction with molecular masses below 3 kDa (PSH-3kDa) from a peach seed hydrolysate 2 
demonstrated high angiotensin converting enzyme (ACE) inhibitory activity (concentration to inhibit 3 
50% ACE (IC50) = 16.4 µg/mL) in our previous work. This work proposes a further study of this highly 4 
active fraction. RP-HPLC enabled to isolate two fractions (F3 and F4) with high inhibitory activity (IC50 5 
= 2.0 ± 0.5 µg/mL and 1.2 ± 0.2 µg/mL, respectively). Peptide analysis by LC-Q-TOF-MS/MS using 6 
reverse-phase and hydrophilic interaction chromatography enabled to identify 33 peptides within both 7 
fractions. Among them, peptide IYSPH showed the highest capacity. The lack of cytotoxicity of peptides 8 
was demonstrated in three different cell lines (HeLa, HT-29, and HK-2). Oral administration of PSH-9 
3kDa fraction or peptide IYSPH caused a significant systolic blood pressure reduction (-30 mmHg) on 10 
spontaneously hypertensive rats after 3-6 h treatment. 11 
 12 
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Hypertension is a cardiovascular risk factor that can lead to stroke, myocardial infarction, cardiac 17 
failure, dementia, renal failure, and even blindness.1, 2 According to the World Health Organization 18 
(WHO), the global prevalence of raised blood pressure (defined as systolic and/or diastolic blood 19 
pressure equal, or above, 140/90 mmHg) in adults was around 22% in 2014.1 20 
Renin-angiotensin system plays an important role in the regulation of blood pressure. It is based on 21 
different enzymatic reactions where angiotensin converting enzyme (ACE) is involved.3 ACE is a 22 
multifunctional zinc containing enzyme located in different tissues in mammalian species.2, 4, 5 ACE 23 
catalyzes the conversion of the decapeptide angiotensin I (ANG I), derived from angiotensinogen, to the 24 
octapeptide angiotensin II (ANG II) by the release of peptide carboxyl-terminal histidyl-leucine (HL).3,6 25 
ANG II induces vasoconstriction and stimulates the release of aldosterone from adrenal cortex. 26 
Moreover, ACE also catalyzes the degradation of the vasodilator bradykinin.4 Synthetic drugs such as 27 
Captopril, Enalapril, Lisinopril have been employed to inhibit excessive ACE activity in hypertension 28 
treatment. Despite their effectiveness, undesirable side effects such as dry cough, edema, and other health 29 
complications usually appear after long-term administration.7 At this regard, some peptides have 30 
demonstrated potent ACE-inhibitory activity and many interesting studies are being carried out to find 31 
out their usefulness to reduce moderate levels of hypertension.8, 9  32 
Many by-products from food processing present high contents of valuable compounds such as 33 
proteins.10 Our research group has reported that fruit stones belonging to Prunus and Olea europaea, 34 
contain seeds with a high protein content. Protein digestion with different enzymes has enabled to obtain 35 
peptides with antioxidant, hypocholesterolemic, and antihypertensive properties from plum, cherry, 36 
apricot, peach, and olive seeds.11-16 Within hydrolysates, that obtained with thermolysin enzyme from 37 
the peach seed proteins (PSH) showed the highest in vitro ability to inhibit ACE. Moreover, most 38 
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antihypertensive peptides in this hydrolysate were in the fraction passing through 3 kDa cut-off 39 
ultrafiltration filters (PSH-3kDa).13 Nevertheless, the usefulness of these studies is relative if no further 40 
research is carried out to demonstrate the in vivo ability of “supposed” antihypertensive peptides.  41 
This work aims to further study of peptides in fraction PSH-3kDa from peach seeds, which exerted a 42 
potent ACE-inhibitory capacity in our previous work 13. Peptides in fraction PSH-3kDa were fractionated 43 
by RP-HPLC and their in vitro ACE inhibition activity was determined. Peptides in most active fractions 44 
were identified by tandem mass spectrometry using two orthogonal chromatographic modes for the 45 
comprehensive separation of peptides. Selected peptides were synthesized and their activity and 46 
cytotoxicity were evaluated. Finally, an in vivo study was conducted to demonstrate the antihypertensive 47 
activity of peptides when administered to spontaneously hypertensive rats. 48 
Materials and methods  49 
Materials 50 
All chemicals and reagents were of analytical grade. Milli-Q water was obtained using a Milli-Q 51 
system from Millipore (Bedford, MA, USA). Acetonitrile (ACN) of HPLC-and MS-grade, hexane, and 52 
acetone were acquired from Scharlau Chemie (Barcelona, Spain). Thermolysin, pepsin, pancreatin, 53 
angiotensin converting enzyme (ACE) from rabbit lung, ammonium bicarbonate, dithiothreitol (DTT), 54 
sodium hydroxide, acetic acid (AA), N-(2-hydroxyethyl)-1-piperazinyl-N’-(2-ethanesulfonic) acid 55 
(HEPES), hippuryl-L-histidyl-L-leucine (HHL), trifluorocetic acid (TFA), 3-(4,5-dimethyl-2-thiazolyl)-56 
2,5 diphenyl tetrazolium bromide (MTT), Dubelcco’s modified eagle medium (DMEM), fetal bovine 57 
serum (FBS), phosphate-buffered saline (PBS), dimethylsulphoxide (DMSO), and Captopril were from 58 
Sigma-Aldrich (St. Louis, MO, USA). Tris(hydroxymethyl)aminomethane (Tris), hydrochloric acid 59 
(HCl), sodium phosphate, and sodium dodecyl sulphate (SDS) were purchased from Merck (Darmstadt, 60 
Germany). Peptides IYSPH (615.3 g/mol), IYTPH (629.3 g/mol), ILMH (512.3 g/mol), IMAPH (567.3 61 
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g/mol), IFSPR (618.3 g/mol), VAIP (398.2 g/mol), PILNDE (699.3 g/mol), and ALPDEV (642.3 g/mol) 62 
were synthesized by GenScript Corp. (Piscataway, NJ, USA) with a purity above 95%. Peaches were 63 
purchased in a local market (Alcalá de Henares, Madrid, Spain).  64 
Cell lines 65 
Cell lines from human cervical cancer (HeLa), human colon cancer (HT-29), and human renal 66 
proximal tubule epithelial (HK-2) were acquired from the American Type Culture Collection ATCC 67 
(Rockwell, MD, USA). 68 
Protein extraction  69 
Protein extraction was carried out using the method described by Vásquez-Villanueva et al.13 Briefly, 70 
a 100 mM Tris-HCl buffer (pH 7.5) containing 0.5% (w/v) SDS and 0.5% (w/v) DTT was added to 30 71 
mg of dried and defatted peach seeds. The mixture was sonicated for 1 min at 30% of amplitude using a 72 
high intensity focused ultrasound probe. After sonication, the extract was centrifuged at 4000 xg for 10 73 
min and extracted proteins were precipitated with cold acetone by keeping in the fridge for 15 min. Then, 74 
cold acetone was removed and precipitated proteins were dried and kept for enzymatic digestion. 75 
Enzymatic protein digestion 76 
Isolated peach seed proteins were enzymatically hydrolyzed as previously reported by Vásquez-77 
Villanueva et al.13 Isolated proteins were dissolved in 5 mM phosphate buffer (pH 8.0) and thermolysin 78 
enzyme was added at an enzyme/substrate ratio of 0.1 g enzyme/g protein. The blend (5 mg/mL; total 79 
volume, 5 mL) was incubated at 50 °C for 4 h. Afterwards, the enzyme was inactivated by increasing the 80 
temperature up to 100 ºC following by the centrifugation, at 4500 xg for 5 min, and the supernatant was 81 
collected. Molecular mass cut-off filters of 3 kDa from Merck Millipore (Tullagreen, Ireland) were 82 
employed for the fractionation of the whole hydrolysate. The permeate was collected and named as PSH-83 
3kDa. Peptide concentration in this fraction was 3.5 mg/mL. 84 
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The in vitro gastrointestinal digestion (GID) was carried out following the method used by Vásquez-85 
Villanueva et al.13 Briefly, samples were adjusted at pH 2.0 with 1 M HCl and digestion with pepsin 86 
enzyme (1:35, enzyme: substrate ratio) was carried out at 37 °C for 1 h. Then, samples were adjusted to 87 
pH 5.0 with 0.1 M NaHCO3 and to pH 7.0-8.0 with 0.1 M NaOH and digestion with pancreatin enzyme 88 
(1:25, enzyme: substrate ratio) was carried out at 37 °C for 3 h. The reaction was stopped by heating at 89 
95 °C for 15 min. 90 
RP-HPLC separation 91 
PSH-3 kDa fraction, with a peptide concentration of 3.5 mg/mL, was further fractionated by using 92 
an HPLC system (from Agilent Technologies, Waldbron, Germany)  equipped with a quaternary pump, 93 
a fraction collector (both 1100 Series), an automatic injector, and a variable wavelength detector (both 94 
1265 Series). A reverse phase column Jupiter 4 µm Proteo 90 Å (250 mm x 10 mm) from Phenomenex 95 
(Torrance, CA, USA) was employed. Mobile phases were: 0.1% TFA/water (v/v) (mobile phase A) and 96 
0.1% TFA/ACN (v/v) (mobile phase B). Elution gradient was: 20% B for 5 min, 25-30 % B in 15 min, 97 
and 30-40% B in 15 min at a flow rate of 1 mL/min. The injected volume, was 600 µL and the separation 98 
temperature was set at 25 °C. Detection wavelengths were set at 210, 254, and 280 nm (for UV detection), 99 
and λexc 280 and λem 360 nm (for fluorescence detection). Every sample was injected four times and 100 
fractions were collected every 5 min from minute 10. Eight fractions were collected, dried in a centrifugal 101 
evaporator (Concentrator Plus, Eppendorf, Hamburg, Germany), and stored at -20 °C until their use. 102 
Before ACE-inhibitory capacity evaluation, every fraction was dissolved in the initial volume of buffer 103 
(2400 µL = 4 x 600 µL). Afterwards, peptide concentration were determined following the method 104 
described in a previous work by Vásquez-Villanueva et al.13 105 
ACE-inhibitory capacity assay 106 
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ACE-inhibitory capacity was measured as previously described in Vásquez-Villanueva et al.17 107 
Briefly, 2.5 µL of sample was mixed with 17.5 µL of 50 mM HEPES, 5 µL of 1.3 mg/mL HHL (in 50 108 
mM HEPES at a pH 8.3 and containing 300 mM NaCl), and 10 µL of an ACE solution (0.05 U/mL). The 109 
reaction mixture was incubated at 37 °C. After 4 h the reaction was stopped with cold ACN (50 µL). The 110 
hippuric acid formed was determined by RP-HPLC using a Zorbax SB-C18 column (0.5 x 150 mm, 5 111 
µm) from Agilent. Mobile phases were: 0.05% TFA/water (v/v) (mobile phase A) and in 0.05% 112 
TFA/ACN (v/v) (mobile phase B). The linear gradient was 5-95% B in 12 min at a flow rate of 20 113 
µL/min. The injected volume was 1 µL and temperature was set at 25 °C. Detection wavelength was set 114 
at 228 nm. ACE inhibition was expressed as IC50 (peptide concentration required to inhibit a 50% of 115 
ACE activity). 116 
Cytotoxicity studies 117 
Cytotoxic effect of peptide fractions and synthesized peptides was evaluated using the MTT assay.18 118 
Two cancer cell lines (HeLa and HT-29) and healthy cell line (HK-2) were employed. Cells were cultured 119 
(1.0×104 viable cells/well) in DMEM containing penicillin-streptomycin, and 10% FBS, and incubated 120 
at 37 °C in a humidified atmosphere (5% CO2). Samples were added to cells at increasing concentrations 121 
and incubated for 24 h. Afterwards, 5 mg/mL MTT solution was added to each well in a 1:10 ratio (cell 122 
volume: MTT stock solution volume). After 4 h, the MTT solution was removed, cells were washed 123 
carefully with PBS, and 500 μL of DMSO was added to dissolve formazan crystals formed by viable 124 
mitochondria. Optical density was measured at 570 nm using an automated microplate reader (Model 125 
ELX 800, Bio-tek instruments, Winooski, VT, USA). Cytotoxicity was expressed as the percentage of 126 
cell viability, considering controls (untreated cells) as 100% viable.  127 
In vivo antihypertensive effect 128 
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In vivo experiments were performed using 25-40-week-old (382 ± 43 g) male spontaneously 129 
hypertensive rats (SHRs) obtained from Envigo (NJ, USA). All experiments were approved by the ethical 130 
committee of the University of Alcalá following European Directive 2010/63/UE and Royal Decree 131 
53/2013 of the Spanish Ministry of Economy and Competitiveness. In all experiments, the number of 132 
animals was six. The animals were kept at 23 °C under 12 h light/dark cycles. Animals could drink tap 133 
water and were fed with a standard diet (Global diet 2014, Envigo, NJ, USA) ad libitum during the 134 
experiments. Peptides dissolved in water up to a final volume of 1 mL were orally administered to the 135 
animals by gastric intubation, between 9 and 10 a.m. The antihypertensive effect was evaluated for the 136 
peptide fraction PSH-3kDa (10 mg/kg) and for the peptide IYSPH (1.5 mg/kg). Tap water was used as 137 
negative control and captopril (10 mg/ kg), as positive control. The systolic blood pressure (SBP) of 138 
SHRs was measured by the non-invasive tail-cuff method using a blood pressure monitor (Pressure Meter 139 
LE 5001, PanLab Harvard Apparatus, Harvard, UK). Before blood pressure measurements, the rats were 140 
kept at around 30 °C for 15 min. At least, five measurements were taken, and the average of all of them 141 
was obtained. All measurements were taken by the same person, under the same conditions, and in the 142 
same environment to minimize stress-induced variations in blood pressure.  143 
Peptide identification by RP-HPLC 144 
Peptides in most active fractions were identified by RP-HPLC-MS/MS and HILIC-MS/MS following 145 
the method reported by Vásquez-Villanueva et al. 17 with some modifications. An HPLC system 146 
equipped with a quaternary pump (1100 Series), an automated injector, and a variable wavelength (both 147 
1265 Series) and coupled to a Quadrupole-Time-of-Flight (Q-TOF) mass spectrometer (6350 Series), all 148 
from Agilent Technologies, were used. RP-HPLC column was an Ascentis Express Peptide ES-C18 (100 149 
mm x 2.1 mm I.D., 2.7 µm particle size) with a guard column (5 mm x 2.1 mm, 2.7 µm particle size) 150 
from Supelco (Bellefonte, PA, USA). Mobile phases were: 0.3% AA/water (v/v) (mobile phase A) and 151 
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0.3% AA/ ACN (v/v) (mobile phase B). Elution gradient was: 3% B for 3 min and 3-25 % B in 30 min. 152 
HILIC column was an Ascentis Express column (100 mm x 2.1 mm I.D., 2.7 µm particle size) with a 153 
guard column (5 mm x 2.1 mm, 2.7 µm particle size), also from Supelco. Mobile phases were: 65 mM 154 
ammonium acetate in ACN (mobile phase A) and 65 mM ammonium acetate in water (mobile phase B). 155 
Elution gradient was: 5-20 % B in 20 min and 20-30% B in 15 min at a flow rate of 0.3 mL/min. The 156 
injected volume was 10 µL and temperature was set at 25 °C. The UV absorbances were recorded at 210, 157 
280, and 254 nm. 158 
Mass spectrometry operated in the positive ion mode using a scanning range from 100 to 1500 m/z. 159 
Auto MS/MS was employed and spectra were analyzed by the de novo sequencing tool using PEAKS 160 
Studio 7 from Bioinformatic Solutions Inc. (Waterloo, ON, Canada). Only peptides with an average local 161 
confidence (ALC, expected percentage of correct amino acid in the peptide sequence) equal or above 162 
90% and a good precursor pattern were considered valid. Identifications were carried out using three 163 
independent samples injected by duplicate. 164 
Statistical analysis 165 
Three independent replicates, injected by duplicate, were used in all experiments. All results were 166 
expressed as mean ± standard deviation. In in vivo experiments, the decrease in SBP was expressed as 167 
mm Hg ± standard deviation for 5-6 measurements. To compare different treatments and to evaluate the 168 
effect of time-course within experiments, data were analyzed by one-way ANOVA using Statgraphics 169 
Centurion version XVII (Statpoint Technologies, Inc., Warrenton, VA). 170 
Results and discussion 171 
Previous works reported by our research group revealed that plum, cherry, apricot, peach (Prunus 172 
genus), and olive (Olea europaea) seeds proteins could release peptides with high in vitro ACE-173 
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inhibitory capacity when they were enzymatically digested with thermolysin.11-13 Among them, a 174 
significant ACE-inhibitory capacity was shown by peptides in fraction PSH-3kDa, obtained from the 175 
peach seed. Indeed, this fraction showed the lowest value of IC50 (16.4 µg/mL).13-16 Moreover, it was 176 
possible to observe that peptides IYSPH, IYTPH, and IFSRP were within this PSH-3kDa. These peptides 177 
have been observed in most Prunus genus seeds and they were even quantified recently.19 Nevertheless, 178 
there is not a deep knowledge on which peptides are really involved in the observed ACE-inhibition 179 
activity, on their innocuous use in living organisms, and on the in vivo activity of these peptides. 180 
Fractionation of PSH-3kDa 181 
With the purpose to isolate those peptides showing the highest capability to inhibit ACE, and, 182 
therefore, with the highest potential to prevent high blood pressure, PSH-3kDa was further fractionated 183 
by RP-HPLC. After the optimization of the chromatographic method, eight fractions were collected. 184 
Figure 1 depicts the chromatogram obtained for PSH-3kDa fraction and the subfractions collected every 185 
5 min from the minute 10, named as F1 up to F8 (Figure 1A). It is interesting to highlight the presence 186 
of a big peak at 20 min which mainly corresponded to the enzyme autolysis blank (see Figure 1A and 187 
Figure 1B). Nevertheless, the size of this peak in Figure 1A is bigger than the peak in Figure 1B which 188 
could indicate the co-elution of peach peptides at the same time. Figure 1A also depicts the percentage 189 
of ACE-inhibition obtained with every collected fraction. Fractions from F1 to F5 exhibited a percentage 190 
of ACE-inhibition higher than 50% (73.9 ± 0.6%, 56.6 ± 1.5%, 78 ± 3%, 94 ± 2%, 82 ± 9%, respectively) 191 
highlighting the ACE-inhibitory capacity of fraction F4. The IC50 values corresponding to these five 192 
fractions were also evaluated and results are included in Figure 1. The lowest values of IC50 were 193 
observed in F3 and F4 reaching 2.0 ± 0.5 and 1.2 ± 0.2 µg/mL, respectively. These fractions also showed 194 
the lowest peptide concentrations (see Figure 1). Fractions F3 and F4 exhibited higher ACE-inhibitory 195 
capacity than the starting fraction, PSH-3kDa (IC50= 16.4 μg/mL). The lack of relationship between the 196 
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measured IC50 value and the percentage of ACE-inhibition reached by fractions can be explained taking 197 
into account the peptide concentration and peptide composition of fractions. For instance, fraction F1 198 
reached 73.9 ± 0.6% of ACE-inhibition but its IC50 was 54 ± 4 µg/mL. This means that this fraction can 199 
show a high inhibition percentage because peptides are present in a high concentration and, thus, it needs 200 
a high peptide concentration for the inhibition of ACE to 50%. On the other hand, F3 fraction reached 201 
78 ± 3% of ACE-inhibition but its IC50 was 2.0 ± 0.2 µg/mL. Thus, F3 can reach a high percentage of 202 
ACE-inhibition despite the peptides, in this fraction, are in a lower concentration. Due to the lowest IC50 203 
values showed by F3 and F4, these fractions were selected for further studies.  204 
Peptide identification in F3 and F4 subfractions 205 
Subfractions F3 and F4 from PSH-3 kDa were analyzed by HPLC-MS/MS using RP-HPLC and 206 
HILIC modes and de novo tool for the identification of the amino acid sequences. RP is the 207 
chromatographic mode most widely employed in the identification of peptide sequences. Nevertheless, 208 
RP-HPLC is limited to peptides with low polarity while polar peptides are eluted in the dead volume. 209 
Thus, the combined use of RP-HPLC and HILIC enabled the comprehensive separation and identification 210 
of all peptides. Table 1 summarizes the sequence of all identified peptides in fractions F3 and F4, along 211 
with their molecular masses, ALC, retention time, and mass accuracy. 212 
Several peptides were identified in F3 and F4, even more than those already identified when 213 
analyzing the whole PSH-3 kDa, in a previous work.13 This can be explained considering the further 214 
separation of peptides in F3 and F4 which enables the detection of additional peptides, whose ionization 215 
was probably suppressed when analyzing the whole PSH-3 kDa. The separation by RP-HPLC allowed 216 
the identification of 11 peptides in F3, and 11 in F4, meanwhile, by using HILIC mode, 14 peptides were 217 
identified in F3 and 11 in F4. Since some peptides were simultaneously observed by RP-HPLC and 218 
HILIC, an overall of 19 peptides were the peptides identified in fraction F3 and 15 in fraction F4. Among 219 
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the identified peptides, LYSPH, LYTPH, and LFSPR had been previously identified in peach, plum, and 220 
cherry seeds hydrolysates that showed ACE-inhibition capacity.11-13 The remaining peptides were newly 221 
sequenced. 222 
A recent proteomic study reported by González-García et al.,20 enabled the identification of proteins 223 
in peach and plum seeds. The comparison of peptides sequences with identified proteins enabled to find 224 
out the correct sequences in cases where I/L amino acids were present since both have the same molecular 225 
mass. Thus, our peptide sequences are IMAPH, ILMH, IYTPH, IFSPR (in F3), IYSPH (in F3/F4) and 226 
PILNDE (in F4) instead of LMAPH, LLMH, LYTPH, IFSPR, LYSPH and PILNDE. Moreover, some 227 
peptides were identified within sequences of 11S globulins. Globulins are storage proteins present in 228 
seeds that are required for the development and growth of seeds. For instance, IYTPH was found in a 229 
fragment of Prunin 2 and Pru 2 proteins, IYSPH, IFSPR, ALPDEV, and VAIP in fragments of Prunin 1, 230 
and PILNDE in Pru 2. Other peptides such as IMAPH and ILMH were within sequences of proteins that 231 
were identified by homology to other plants species such as Sesamum indicum (sesame) and Oryza sativa 232 
(rice).20  233 
These peptide sequences were searched within BIOPEP and AHTPDB databases (which are 234 
databases focused on bioactive and antihypertensive peptides, respectively) but non-coincidences of 235 
bioactive peptides were found.21, 22 236 
Regarding their characteristics, all peptides were short size and showed molecular masses lower than 237 
1 kDa. A significant presence of hydrophobic amino acid residues such as A, F, I, L, M, P, and V, and 238 
aromatic amino acids such as F and Y in the first three C-terminal positions, was observed. These are 239 
typical features for antihypertensive peptides. 23-25 ACE has E, K, R, and Y amino acid residues at the 240 
active site and three hydrophobic binding subsites. Zhou et al. determined that peptides with the above 241 
mentioned characteristics, theoretically, had high affinity for these active sites which favored the 242 
blockade of ACE.26 243 
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Unlike expected, the hydrophobicity of peptides observed by RP-HPLC was similar to those 244 
separated by HILIC. Indeed, hydrophobicity plus aromatic residues observed by RP-HPLC in F3 and F4 245 
were 67% and 60%, respectively, while by HILIC, the contribution of hydrophobic plus aromatic amino 246 
acids was 76% and 64%, respectively. This fact can be explained by the amino acid position in peptide 247 
sequences, and by the presence of basic amino acids such as H, K, and R, which are positively charged 248 
within peptide sequences separated by HILIC.27 Finally, Figure 2 shows, as an example, the total ion 249 
chromatogram (TIC) corresponding to fraction F3 obtained by RP-HPLC and HILIC modes, and the 250 
fragmentation spectrum of IYSPH peptide. As observed, TIC obtained by RP-HPLC resulted in a more 251 
crowded chromatogram than to the observed by HILIC. Moreover, IYSPH spectrum shows all y-ions 252 
obtained after MS/MS fractionation. 253 
Characterization of synthesized peptides  254 
Based on the hydrophobic and aromatic amino acid content, the differentiation of I/L, and their 255 
potential as antihypertensive peptides, eight peptides from Table 1 were selected for their synthesis and 256 
further study. Synthesized peptides were: IYSPH, IMAPH, ILMH, IYTPH, IFSPR, VAIP, PILNDE, and 257 
ALPDEV. The percentage of ACE-inhibition and their IC50 were evaluated and results are grouped in 258 
Table 2.  259 
The highest ACE-inhibitory effect was obtained for IFSPR and IYSPH while peptides IYTPH and 260 
VAIP reached a moderate percentage of ACE-inhibition. Concerning IC50 values, peptide IYSPH exerted 261 
the highest ACE-inhibitory capacity (IC50 = 24 ± 3 µg/mL (39 ± 5 µM)), while IFSPR (IC50 = 31 ± 2 262 
µg/mL (50 ± 4 µM)) and VAIP exhibited moderate IC50 (142 ± 22 µg/mL (358 ± 55 µM)). The IC50 263 
values of synthesized peptides from peach seeds are higher than those obtained for F3 and F4 fractions 264 
(2.0 ± 0.5 µg/mL and 1.2 ± 0.2 µg/mL, respectively). Similar results were obtained by Ben Henda et al. 265 
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with synthesized peptides from Tilapia (hydrolysates with molecular masses < 1 kDa).28 This behavior 266 
could be due to the presence of synergistic effects among peptides with F3 and F4 fractions. 267 
In order to evaluate the resistance to gastrointestinal enzymes, peptides were subjected to in vitro 268 
gastrointestinal digestion (GID). IC50 values after GID are also shown in Table 2. After simulated GID, 269 
peptides IFSPR and IYSPH kept their activity above 50% of ACE-inhibition although IC50 value 270 
corresponding to peptide IFSPR was doubled (from 31 to 67 µg/mL) and the corresponding to the IYSPH 271 
peptide slightly increased (from 24 to 35 µg/mL). The presence of proline amino acid residue within 272 
three C-terminal position probably makes peptide IYSPH to be less susceptible to intestinal peptidases.29 273 
The IC50 for peptide VAIP after GID could not be evaluated since the percentage of ACE inhibition was 274 
below 50 %. 275 
Cytotoxicity of peptides 276 
Cytotoxicity of peptides in PSH-3kDa, F3 and F4 fractions, and IYSPH peptide was evaluated by the 277 
MTT assay at different concentrations. This method measures the mitochondrial dehydrogenase activity 278 
in living cells.18 Since each cell line has their own sensitivity, it is recommended the use of different cell 279 
lines.30 Cells were treated with increasing concentrations of samples several times above IC50 value. 280 
Figure 3, shows the viability of three different kinds of cells (HeLa, HT-29, and HK-2) in presence of 281 
peptides from PSH-3kDa, F3 and F4 fractions, and IYSPH peptide. All tested peptides exerted similar 282 
tendency, even at high concentrations, reaching a constant value around 80% of cell viability, (always 283 
above IC50). Results demonstrated that studied samples did not show cytotoxic effects after 24 h of 284 
incubation and that their use in in vivo future assays was safe.  285 
In vivo antihypertensive effects in SHRs 286 
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In vitro results are often not well correlated with results obtained by in vivo experiments. Thus, in 287 
vivo studies are required to assure the antihypertensive effect which greatly depends on the capacity of 288 
compounds to reach target organs. In vivo assays were carried out with fraction PSH-3kDa that 289 
significantly inhibited ACE and that could be easy prepared from peach seed. Moreover, synthetic 290 
peptide IYSPH, that exerted a high ACE inhibition, was also employed in in vivo assays. Figure 4 depicts 291 
the decrease in SBP after the oral administration of the above-mentioned peptides in comparison to 292 
captopril (a potent ACE inhibitor), used as positive control. Oral administration of PSH-3kDa and peptide 293 
IYSPH at doses of 10 mg/kg and 1.5 mg/kg, respectively, induced a significant reduction of SBP, from 294 
187 mmHg (before treatment) to 156 mmHg (after treatment) (p-value < 0.05). Maximum 295 
antihypertensive effect was observed between 3-6 h post administration. Captopril at 10 mg/kg showed 296 
its maximum hypotensive effect at 3 h after administration, which is statistically higher than the observed 297 
for peptide IYSPH and fraction PSH-3kDa (p-value < 0.05) at same time-course. Moreover, there were 298 
no statistical differences between hypotensive effects of captopril and peptides at 6 h after administration 299 
(p-value > 0.05). The antihypertensive effect of these samples was almost reverted 24 h after 300 
administration. These results are comparable to those obtained for lactopeptides VPP and IPP that have 301 
also proven their antihypertensive activity in SHR. While peptide IYSPH and fraction PSH-3kDa enabled 302 
a SBP reduction around -30 mmHg, the reduction in SBP caused by VPP and IPP peptides is around -29 303 
mmHg and -24 mmHg, at 6 h after administration, respectively. 31 Recently, Liu et al. reported 304 
antihypertensive peptides from hazelnut protein hydrolysate. 32  Within peptides identified, a peptide with 305 
the sequence amino acid YLVR showed a significant reduction in SBP around -40 mmHg at 8 h after 306 
administration. 32 Similarly, Dang et al. found a peptide with sequence LVLPGE in broccoli which 307 
decreased SBP around -40 mmHg at 8 h after administration. 33 Despite greater hypotensive effect was 308 
observed, higher doses (10 mg/kg), in both cases, than for peptide IYSPH (1.5 mg/kg) were employed.  309 
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Moreover, the required concentration of peach seed hydrolysate to observe the reduction of SBP was 310 
low. Indeed, Wang et al. prepared a rice bran protein hydrolysate that showed a suppressive effect by the 311 
administration of 50 mg hydrolysate/kg rat,34 5 times higher than the required in our case. Other example 312 
is the antihypertensive effect of palm kernel cake protein hydrolysate reported by Zarei et al., which 313 
significantly inhibited hypertension at a dose of 75 mg/kg.25 314 
Taking into account the PSH-3 kDa and IYSPH concentrations required to decrease SBP in SHR, 315 
and following the Food and Drug Administration draft guidelines,35 it was possible to calculate the 316 
corresponding human equivalent dose that was 0.243 mg/kg, in the case of peptide IYSPH, and 1.62 317 
mg/kg, for PSH-3kDa fraction. These results demonstrate the significant potential of using peach seed 318 
by-product for the production of bioactive peptides with high hypotensive properties. Nevertheless, 319 
additional evaluations are required to elucidate the mechanism of PSH-3kDa and peptide IYSPH for their 320 
antihypertensive potency in SHRs. 321 
In summary, peptides isolated from a peach by-product have demonstrated potent antihypertensive 322 
activity during in vivo experiments carried out with hypertensive rats. A high ACE-inhibitory activity 323 
was detected in two fractions (F3 and F4) obtained after fractionation by ultrafiltration and RP-HPLC of 324 
the starting peach seed hydrolysate. Sequencing by HPLC-MS/MS using two orthogonal 325 
chromatographic modes, RP-HPLC and HILIC, guaranteed the comprehensive detection of peptides in 326 
these fractions. Most peptides displayed typical features of antihypertensive peptides such as short size 327 
and a high content in hydrophobic and aromatic amino acids residues.36, 37 Moreover, some of them also 328 
resisted gastrointestinal digestion. Additionally, a cytotoxic study using three different cell lines (HeLa, 329 
HK-2, and HT-29) revealed that these peptides did not result in a significant reduction in cell viability 330 
and could be administered to living organisms. The oral administration of PSH-3kDa peptide fraction or 331 
peptide IYSPH produced a 16% reduction of systolic blood pressure (around 30 mm Hg) after 3-6 h 332 
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treatment. Results suggest that peach seed, which is an underused by-product, is useful for the production 333 
of peptides with effective antihypertensive activity that can be employed for the development of 334 
nutraceuticals and functional foods.  335 
Abbreviations Used 336 
ACE  Angiotensin converting enzyme 337 
ALPDEV  Alanine- Leucine- Proline- Aspartic Acid- Glutamic Acid- Valine 338 
ANG I  Angiotensin I  339 
ANG II  Angiotensin II  340 
HeLa   Cervical cancer cells 341 
HK-2   Human renal proximal tubule epithelial cells 342 
HT-29  Human colon cancer cells 343 
IFSPR  Isoleucine- Phenylalanine- Serine- Proline- Arginine 344 
ILMH   Isoleucine- Leucine- Methionine- Histidine 345 
IMAPH  Isoleucine- Methionine- Alanine- Proline- Histidine 346 
IYSPH  Isoleucine-Tyrosine-Serine-Proline-Histidine 347 
IYTPH  Isoleucine-Tyrosine-Threonine-Proline-Histidine 348 
PILNDE  Proline- Isoleucine- Leucine- Asparagine- Aspartic Acid- Glutamic Acid 349 
PSH   Peach seed hydrolysates  350 
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PSH-3kDa  Peach seed hydrolysate containing peptides with molecular weights            351 
 below 3 kDa 352 
SBP  Systolic blood pressure 353 
SHRs  Spontaneously hypertensive rats 354 




References  357 
(1) World Health Organization (WHO). Global Status Report on noncommunicable diseases 2014 URL: 358 
(http://apps.who.int/iris/bitstream/10665/148114/1/9789241564854_eng.pdf). Accessed March 2019. 359 
(2) Das, U. N. Is angiotensin-II an endogenous pro-inflammatory molecule? Med. Sci. Monit. 2005, 11, 360 
155-162. 361 
(3) Struthers, A. D.; McDonald, T. M. Review of aldosterone and angiotensin II-induced target organ 362 
damage and prevention. Cardiovasc. Res. 2004, 21, 663-670. 363 
(4) Paul, M.; Poyan Mehr, A.; Kreutz, R. Physiology of local renin-angiotensin systems. Physiol. Rev. 364 
2006, 86, 747-803. 365 
(5) Mehta, P. K.; Griendling, K. K. Angiotensin II cell signaling: physiological and pathological effects 366 
in the cardiovascular system.  Am. J. Physiol. Cell Physiol. 2007, 292, 82-97. 367 
(6) Curtiss, C.; Chon, J. N.; Vrobel, T.; Francious, J. A. Role of the rennin-angiotensin system in the 368 
systemic vasoconstriction of chronic congestive heart failure. Circulation, 1978, 58,763–70. 369 
(7) Sweeting, M. J.; Thompson, S. G.; Brown, L. C.; Greenhalgh, R. M.; Powell, J. T. Use of angiotensin 370 
converting enzyme inhibitors is associated with increased growth rate of abdominal aortic aneurysms. J. 371 
Vasc. Surg. 2012, 52, 1-4. 372 
(8) Puchalska, P.; Marina, M. L.; García, M. C. Isolation and characterization of peptides with 373 
antihypertensive activity in foodstuff. Crit. Rev. Food Sci. Nutr. 2015, 55, 521-551. 374 
(9) Rizzello, C. G.; Tagliazucchi, D.; Babini, E.; Rutella, G. S.; Taneyo, Saa D. L.; Gianotti, A. Bioactive 375 
peptides from vegetable food matrices: Research trends and novel biotechnologies for synthesis and 376 
recovery. J. Funct. Foods, 2016, 27, 549-569.  377 
20 
 
(10) Varzakas, T.; Zakynthinos, G.; Verpoort, F. Plant food residues as a source of nutraceuticals and 378 
functional foods. Foods, 2016, 5, 88. 379 
(11) González-García, E.; Puchalska, P.; Marina, M. L.; García, M. C. Fractionation and identification 380 
of antioxidant and angiotensin-converting enzyme-inhibitory peptides obtained from plum (Prunus 381 
domestica L.) stones. J. Funct. Foods, 2014, 19, 376-384. 382 
(12) García, M. C.; Endermann, J.; González-García, E.; Marina, M. L. Identification of antioxidant and 383 
antihypertensive peptides in cherry (Prunus cereasus L.) kernels by HPLC-Q-TOF-MS. J. Agric. Food 384 
Chem. 2015, 63, 1514-1520. 385 
(13) Vásquez-Villanueva, R.; Marina, M. L.; García, M. C. Revalorization of a peach (Prunus persica 386 
(L.) Batsch) byproduct: Extraction and characterization of ACE-inhibitory peptides from peach stones. 387 
J. Funct. Foods, 2015, 18, 137-146. 388 
(14) García, M. C.; González-García, E.; Vásquez-Villanueva, R.; Marina, M. L. Apricot and other seed 389 
stones: amygdalin content and the potential to obtain antioxidant, angiotensin I converting enzyme 390 
inhibitor and hypocholesterolemic peptides. Food Funct. 2016, 7, 4693-4701. 391 
(15) Vásquez-Villanueva, R.; Marina, M. L.; García, M. C. Identification by hydrophilic interaction and 392 
reversed-phase liquid chromatography-tandem mass spectrometry of peptides with antioxidant capacity 393 
in food residues. J. Chromatogr. A 2016, 1428, 185-192.  394 
(16) Esteve, C.; Marina, M. L.; García, M. C. Novel strategy for the revalorization of olive (Olea 395 
europaea) residues based on the extraction of bioactive peptides. Food Chem. 2015, 167, 272-280. 396 
(17) Vásquez-Villanueva, R.; Muñoz-Moreno, L.; Carmena, M. J.; Marina, M. L.; García M. C. In vitro 397 
antitumor and hypotensive activity of peptides from olive seeds. J. Funct. Foods, 2018, 42, 177-184. 398 
21 
 
(18) Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation 399 
and cytotoxicity assays. J. Immuno.l Methods.1983, 65, 55-63. 400 
(19) González-García, E.; García, M. C.; Marina, M. L. Capillary liquid chromatography-ion trap-mass 401 
spectrometry methodology for the simultaneous quantification of four angiotensin-converting enzyme-402 
inhibitory peptides in Prunus seed hydrolysates. J. Chromatogr. A 2018, 1540, 47-54. 403 
(20) González-García, E.; Marina, M. L.; García, M. C.; Righetti, P. G.; Fasoli, E. Identification of plum 404 
and peach seed proteins by nLC-MS/MS via combinatorial peptide ligand libraries. J. Proteomics, 2016, 405 
48, 105-112. 406 
(21) Minkiewicz, P.; Dziuba, J.; Iwaniak, A.; Dziuba, M.; Darewicz, M. BIOPEP database and other 407 
programs for processing bioactive peptide sequences. J. AOAC Int. 2008, 91, 965-980. 408 
(22) Kumar, R.; Chaudhary, K.; Sharma, M.; Nagpal, G.; Chauhan, J. S.; Singh, S.; Gautam, A.; Raghava, 409 
G. P. S. AHTPDB: a comprehensive platform for analysis and presentation of antihypertensive peptides. 410 
Nucleic Acids Res. 2015, 43, 956-962. 411 
(23) Vermeirssen, V.; Van Camp, J.; Verstraete, W. Bioavailability of angiotensin I converting enzyme 412 
inhibitory peptides. Br. J. Nutr. 2004, 92, 357-366. 413 
(24) Yamamoto, N.; Akino, A.; Takano, T. Antihypertensive effect of the peptides derived from casein 414 
by an extracellular proteinase from lactobacillus helveticus cp 790. J. Dairy Sci. 1994, 77, 917-922. 415 
(25) Zarei, M.; Forghani, B.; Ebrahimpour, A.; Abdul-Hamid, A.; Anwar, F.; Saari, N. In vitro and in 416 
vivo antihypertensive activity of palm kernel protein hydrolysates: sequencing and characterization of 417 
potent bioactive peptides. Ind. Crops Prod. 2015, 76, 112-120. 418 
22 
 
(26) Zhou, Z.; Cheng, C.; Li, Y. Structure-based design and optimization of antihypertensive peptides to 419 
obtain high inhibitory potency against both renin and angiotensin I-converting enzyme. SAR 420 
QSAR Environ. Res.  2015, 26, 1001-1016. 421 
(27) Le Maux, S.; Nongonierma, A. B.; FitzGerald, R. J. Improved short peptide identification using 422 
HILIC-MS/MS: Retention time prediction model based on the impact of amino acid position in peptide 423 
sequence. Food Chem. 2015, 173, 847-854. 424 
(28) Ben Henda, Y.; Bonnet, A.; Nunes González da Silva, O. L.; Boscolo Wilson, R.; Arnaudin, I.; 425 
Bridiau, N.; Maugard, T.; Piot, J.-M.; Sannier, F.; Bordenave-Juchereau, S.  Identification of ace 426 
inhibitory cryptides in Tilapia protein hydrolysate by UPLC-MS/MS coupled to database analysis. J. 427 
Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2017, 1052, 43-50. 428 
(29) Manoharan S, Shuib AS, Abdullah N. Structural characteristics and antihypertensive effects of 429 
angiotensin-I-converting enzyme inhibitory peptides in the renin-angiotensin and kallikrein-kinin 430 
systems. Afr. J. Tradit. Complement. Altern. Med. 2017, 14, 383–406. 431 
(30) Phelan, M.; Aherne, A.; FitzGerald, R. J.; O’Brien N. M. Casein- derived bioactive peptides: 432 
biological effects, industrial uses, safety aspects and regulatory status. Int. Dairy J. 2009, 19, 643–654. 433 
(31) Nakamura, Y.; Yamamoto, N.; Sakai, K.; Takano, T. Antihypertensive effect of sour milk and 434 
peptides isolated from it that are inhibitors to Angiotensin I-Converting Enzyme. J. Dairy Sci. 1995, 78, 435 
1253-1257. 436 
(32) Liu, C.; Fang, L.; Min, W.; Liu, J.; Li, H. Exploration of the molecular interactions between 437 
angiotensin-I-converting enzyme (ACE) and the inhibitory peptides derived from hazelnut (Corylus 438 
heterophylla Fisch). Food Chem. 2018, 245, 471-480. 439 
23 
 
(33) Dan, Y.; Zhou, T.; Hao, L.; Cao, J.; Sun, Y.; Pan, D. In vitro and in vivo studies on the angiotensin-440 
converting enzyme inhibitory activity peptides isolated from broccoli protein hydrolysate. J. Agric. Food 441 
Chem. 2019, 67, 6757-6764. 442 
(34) Shobako, N.; Ogawa, Y.; Ishikado, A.; Harada, K.; Kobayashi, E.; Suido, H.; Kusakari, T.; Maeda, 443 
M.; Suwa, M.; Matsumoto, M.; Kanamoto, R.; Ohinata, K. A novel antihypertensive peptide identified 444 
in thermolysin-digested rice bran. Mol. Nutr. Food Res. 2018, 62, 1700732. 445 
(35) USFDA. Guidance for industry estimating the maximum safe starting dose in initial clinical trials 446 
for therapeutics in adult healthy volunteers. Rockville, MD: US Food and Drug Administration; 2005 447 
(36) García-Mora, P.; Martín-Martínez, M.; Bonache, M.A.; González-Múniz, R.; Peñas, E.; Frias, J.; 448 
Martínez-Villaluenga, C. Identification, functional gastrointestinal stability and molecular docking 449 
studies of lentil peptides with dual antioxidant and angiotensin I converting enzyme inhibitory activities. 450 
Food Chem. 2017, 221, 464-472. 451 
(37) Erdmann, K., Cheung, B.W.Y.; Schroeder, H. The possible roles of food-derived bioactive peptides 452 
in reducing the risk of cardiovascular disease. J. Nutr. Biochem. 2008, 19, 643-654. 453 
Funding sources 454 
This work was supported by the Ministry of Economy and Competitiveness (ref. AGL2016-79010-455 
R), and the Comunidad de Madrid and European funding from FEDER program (project S2018/BAA-456 
4393, AVANSECAL-II-CM). R.V.-V thanks the University of Alcalá for her pre-doctoral contract. 457 
Notes 458 




Figure captions 461 
Figure 1. Purification of PSH-3kDa by RP-HPLC. Chromatogram (A) shows the percentage of ACE-462 
inhibition and the IC50 (µg/mL), for fractions exceeding 50% of ACE-inhibition, vs. time. Next to 463 
chromatogram, the peptide concentration for every fraction exceeding 50% of ACE-inhibition. 464 
Chromatogram (B) shows the hydrolysis blank corresponding to the autolysis of thermolysin enzyme. 465 
Figure 2. Total ion chromatograms (TIC) obtained by RP-HPLC and HILIC coupled to ESI-Q-TOF for 466 
fraction F3 and fragmentation spectrum corresponding to IYSPH peptide. 467 
Figure 3. Percentage of cell viability obtained when treating three different cell lines (HeLa, HT-29, and 468 
HK-2) with fractions PSH-3kDa (A), F3 (B), F4 (C) and with synthesized peptide IYSPH (D).  469 
Figure 4. Time-course of systolic blood pressure (SBP) after oral administration of Captopril (10 mg/kg, 470 
●), PSH-3kDa (10 mg/kg, ■), and peptide IYSPH (1.5 mg/kg, ▲) to SHRs. Changes of SBP from baseline 471 
(time 0) are expressed by the mean ± standard deviation. 472 
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Table 1. Peptide Sequence, Average Local Confidence (ALC), and Molecular Mass of Peptides 










































































































































































































































a Parameters obtained by RP-HPLC. 
b Parameters obtained by HILIC. 
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Table 2. ACE-Inhibition Activity (%) of Synthesized Peptides and IC50 (μg/mL) of Peptides exceeding 
50 % of ACE-Inhibition, before and after Simulated Gastrointestinal Digestion (GID). 
 
*Peptide concentration used to determine the percentage of ACE-inhibition was 0.5 mg/mL.
Peptide 
Sequence 







IMAPH 3 23.8 
   
IYTPH 3 47.5 
   
ILMH 3 38.0 
   
IFSPR 3 75.7 31 ± 2 66 ± 1 67± 5 
IYSPH  3/4 64.8 24 ±3 74 ± 2 35 ± 3 
VAIP 4 51.7 142 ± 22 35 ± 4 
 
ALPDEV 4 6.8 
   
PILNDE 4 10.8 
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